Avid Bioservices Inc (CDMO)

[north40000]

Roche PR re results in Tecentriq Phase 3 trial; rather devoid of numerical data, IMO, but it is the "family" according to some:

http://www.businesswire.com/news/home/20160831006615/en/Phase-III-Study-Showed-Genentech%E2%80%99s-Cancer-Immunotherapy

"SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results for TECENTRIQ from the Phase III study, OAK. The study met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events were consistent with what has been previously observed for TECENTRIQ. Genentech looks forward to presenting full results at an upcoming medical meeting in 2016.

“This is very encouraging news for people living with this disease because lung cancer is the leading cause of cancer deaths around the world. We hope to bring this treatment option to patients as soon as possible.”...[more]